SCHEMBL24359587

SCHEMBL24359587

CCCCC1CCN(c2ccc(CCO)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.45
S1PR1 P21453 1/20 0.44
ADRB2 P07550 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
L3MBTL3 Q96JM7 7/20 0.40
L3MBTL1 Q9Y468 7/20 0.40
DPP4 P27487 2/20 0.40
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
CCND2 P30279 1/20 0.40
CCND3 P30281 1/20 0.40
SPHK1 Q9NYA1 4/20 0.39
MBTD1 Q05BQ5 1/20 0.39
TP53BP1 Q12888 1/20 0.39
ME2 P23368 1/20 0.39
ME1 P48163 1/20 0.39
ME3 Q16798 1/20 0.39
SPHK2 Q9NRA0 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516679 0.85 KDM4E (0.44) HRH3S1PR1MAOAMAOBL3MBTL3
SCHEMBL22856415 0.81 DPP4 (0.41) HRH3S1PR1MAOAMAOBDPP4
SCHEMBL25833691 0.80 MAOB (0.52) HRH3S1PR1MAOAMAOBL3MBTL3
SCHEMBL23696638 0.80 DPP4 (0.40) HRH3DPP4
SCHEMBL23842183 0.80 DPP4 (0.40) HRH3S1PR1MAOAMAOBDPP4
SCHEMBL24359258 0.79 HRH3 (0.46) HRH3S1PR1ADRB2MAOAMAOB
SCHEMBL25192949 0.79 MAPT (0.51) HRH3L3MBTL1DPP4
SCHEMBL15037944 0.79 DPP4 (0.60) HRH3L3MBTL3L3MBTL1DPP4MBTD1
SCHEMBL24359213 0.78 MAPT (0.50) S1PR1ME3
SCHEMBL24093152 0.76 HRH3 (0.50) HRH3ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391731-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF LIANGJIANG MEDICINE CO., LTD. (CN) 2023-12-07 US disclosed
EP-4232437-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF Liangjiang Medicine Co., Ltd. (CN) 2023-08-30 EP disclosed
CN-116529252-A Prodrugs for sustained release of therapeutic agents and uses thereof 重庆两江药物研发中心有限公司 2023-08-01 CN disclosed
WO-2022083679-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF LIANGJIANG MEDICINE CO., LTD. (CN) 2022-04-28 WO disclosed
WO-2022083679-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF LIANGJIANG MEDICINE CO., LTD. (CN) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391731-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF GRPR, SLC2A8, HPGDS HRH3 2090/4885S1PR1 127/4885ADRB2 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.